Evaluation of the relationship between visual improvement with intravitreal injection of Ranibizumab and chorioretinal hemodynamics in retinal vein occlusion with macular edema

Evaluation of the relationship between visual improvement with intravitreal injection of Ranibizumab and chorioretinal hemodynamics in retinal vein occlusion with macular edema - Ranibizumab and chorioretinal blood flow

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019771

Enrollment

Registered

2015-11-13

Start date

2013-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

Duration:12months Quantity:Ramibizumab 0.5mg/injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with macular edema due to retinal vein occlusion who visit Tokyo women's medical university Central foveal thickness over 250 micron. Visual acuity over 0.1

Exclusion criteria

Exclusion criteria: Othe ocular pathology Past history of brain and myocardial infarction. Uncontrolled hypertention. Anti-VEGF treatment for general diseases. Laser, Anti-VEGF, intravitreal injection of steroid and vitrectomy for ocular pathology.

Design outcomes

Primary

Measure	Time frame
Population of visual improvemnt after the first intravitreal injection of Ranibizumab.	—

Countries

Japan

Contacts

Public ContactAkiko Kogure

Tokyo women's Medical University Department of Ophthalmology

kogure.akiko@twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026